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INTRODUCTION 
Long-term use of beta-blockers after acute myocardial infarction (AMI) may reduce total 
mortality by as much as 26% [1].  Given the high incidence of AMI, it has been estimated that if 
all AMI survivors initiated and continued beta-blocker therapy for 20 years in the US alone, as 
many as 4,300 fewer deaths from chronic heart disease and 3,500 fewer repeat AMIs would 
occur in the United States [2].  
 
Guidelines from the American College of Cardiology (ACC), the American Heart Association 
(AHA), and the European Society of Cardiology recommend use of beta-blockers in AMI 
patients without contraindications to such treatment [3-5].  However, post-AMI beta-blocker 
therapy is often underutilized [6-10].  Only 61% of patients who were candidates for post-AMI 
beta-blocker therapy actually initiated it in British Columbia, Canada, between 2001 and 2004 
[9].  Furthermore, post-AMI beta-blockade is maximally effective only when patients adhere to 
the therapy and persist on it over the long-term [11].  However, observed adherence to and 
persistence with post-AMI beta-blocker therapy has also been low among those who initiate such 
therapy [12]. 
 
Little is known about recent patterns and predictors of post-AMI beta-blocker initiation [13] and 
recent trends in adherence to such therapy.  Most studies currently available in the medical 
literature have examined patterns and predictors of beta-blocker therapy only up to 2004 and 
most of this evidence is from North America.  Drug prescribing and utilization patterns can vary 
widely between countries and also within countries over time [14,15].  Thus, we sought to: (1) 
estimate the proportion of patients without contraindications who initiated beta-blocker therapy 
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after AMI in Regione Emilia-Romagna (RER), Italy; (2) examine predictors, including patient 
and clinical characteristics and use of alternative medications, of beta-blocker initiation after 
AMI; and (3) estimate patient adherence to beta-blocker therapy after AMI using data from 2003 
to 2008. 
 
METHODS 
Data source 
We used the healthcare database from RER, comprising all of the approximately 4 million RER 
residents over the period 2003 to 2008.  This database captures health service utilization 
information for the entire region, including hospital discharge abstract data, such as diagnosis 
and procedure codes, and outpatient prescription drug dispensing data.  Individuals can be linked 
across data files with anonymous patient identifiers and can be followed longitudinally.  This 
study complies with the Declaration of Helsinki and was approved by the Institutional Review 
Board of Thomas Jefferson University, Philadelphia, PA.   
 
Cohort identification 
We identified a cohort of patients with AMI comprising all RER residents aged 35 and older 
discharged alive from a regional hospital between January 1, 2004 and December 31, 2007 with 
a primary diagnosis of AMI (ICD-9 codes 410.x1) [16].  The index AMI admission for each 
patient was defined as the first AMI admission identified in the study period.  We excluded 
patients discharged alive but whose length of stay for the index AMI admission was less than 3 
days, as recorded AMI codes may have been for rule-out purposes in these cases [16,17].  
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Patients were also excluded if they died within 30 days of discharge to ensure a minimum time 
window for measuring beta-blockers use in the outpatient setting. 
 
Patients were also excluded if they had absolute or relative contraindications to beta-blockers.  
Specifically, based on primary and secondary inpatient diagnoses in the year prior to index 
hospitalization, we excluded those with hypotension, heart block > 1 degree, sinus bradycardia, 
chronic obstructive pulmonary disease, or peripheral vascular disease.  Patients with asthma were 
also excluded and were identified as those with a prescription record for inhaled corticosteroids 
in the 6 months prior to the index hospitalization or those with a primary or secondary hospital 
discharge diagnosis of asthma in year prior to the index AMI admission.  Patients with type 1 
diabetes mellitus, defined as those who had received insulin in the 6 months prior to or 3 months 
following the index AMI admission, were also excluded [17]. 
 
Covariates 
Potential predictors of beta-blocker initiation were identified from inpatient data and prescription 
drug dispensing data in the year preceding index hospitalization – as early as the beginning of 
2003 (a detailed list of ICD-9-CM codes and of Anatomical Therapeutic Chemical (ATC) 
classification system codes are available from the authors).  We retrieved demographic 
information, including age, gender, and geographic location.  We also collected information on 
cardiovascular health services use, including hospital admissions with primary diagnoses of 
angina, ischemic heart disease, congestive heart failure, and other cardiovascular diseases, as 
well as use of specific medications for cardiovascular conditions, including digoxin, angiotensin-
converting enzyme (ACE) inhibitors, nitrates, beta-blockers, calcium channel blockers, and 
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angiotensin II receptor blockers (ARBs) [18].  Comorbidities were ascertained from non-cardiac 
hospital admissions with primary diagnoses for other conditions that may increase mortality risk 
[18].  We also used the Chronic Condition Drug Group (CCDG), a prescription drug-based 
comorbidity index [19].  CCDGs were developed in the same RER database and have been 
applied in other published studies [14,15,20].  Also, we computed the number of different drug 
products filled in the 6 months before hospitalization as a proxy for health status [21].  Finally, 
we constructed indicator variables for intensity of the in-hospital stay, including length of stay, 
receipt of invasive cardiac procedures, and whether the patient received specialized care defined 
as spending at least part of their stay in the cardiac surgery, intensive care, cardiology, or critical 
care units.  
 
Outcome measures and statistical analysis 
We estimated the proportion of patients in the eligible cohort with at least one record of a 
dispensing for a beta-blocker within 90 days after discharge from the index hospitalization.  We 
conducted a logistic regression analysis to identify which factors were independent predictors of 
beta-blocker initiation in this cohort.  Dichotomous post-AMI beta-blocker use was the 
dependent variable in the model.  All other covariates described above, including demographics, 
comorbid conditions, and cardiovascular health services use, were entered into the model 
simultaneously as independent variables to identify which factors were associated with beta-
blocker use while controlling for all other factors in the model.  Odds ratios (ORs) and their 95% 
confidence intervals were estimated for the association between beta-blocker initiation and each 
of the independent variables.  All analyses were conducted using SAS (version 9.1, Cary, NC). 
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Among cohort members with at least one prescription for a post-AMI beta-blocker, we estimated 
the proportion of days covered (PDC), or medication possession ratio, for beta-blocker therapy at 
6 and 12 months from the first beta-blocker prescription dispensed.  This interval-based PDC is a 
commonly used measure of drug availability and is a function of both adherence to (i.e. patient 
takes prescribed medication according to schedule) and persistence with (i.e. patient continues to 
take therapy) drug therapy over a defined time interval [22,23].  To estimate the 6- and 12-month 
PDCs, we first computed the number of days covered by beta-blockers within each time period 
of interest as the total number of Defined Daily Doses (DDDs) for any type of beta-blocker 
prescribed to each individual [22,24].  The DDD is a technical unit of measurement, used by the 
World Health Organization, which reflects the average adult dose used for the main indication as 
reflected by the Anatomical Therapeutic Chemical (ATC) classification system code [25].  We 
then divided the number of days covered by beta-blockers by 180 and 360 for the 6- and 12-
month estimate, respectively, and multiplied by 100 to arrive at the estimated PDC.  We 
excluded patients who died within 6 and 12 months after the index AMI, from each time interval, 
respectively.  We used a priori PDC cutoffs of ≥80%, 50% to <80%, and <50% to classify 
patients as adherent, moderately adherent, and non-adherent, respectively [6].  We also 
calculated the mean 6- and 12-month PDC among initiators stratified by year of hospitalization 
and performed a Cochran-Armitage test for trend over time in the proportion of initiators who 
were adherent. 
 
RESULTS 
Study Cohort 
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We identified 28,001 patients who met the cohort eligibility criteria.  Of these, 3,634 (13%) were 
excluded because they had one or more contraindications to beta-blockers.  Thus, the final study 
cohort comprised 24,367 eligible patients hospitalized for AMI in RER between 2004 and 2007 
(Table 1).  Selected demographic and clinical information as well as factors related to the index 
hospitalization are reported in Table 1, and are fully reported in the online supplement.  Of the 
eligible cohort, 16,383 (67%) received at least one outpatient dispensing for a beta-blocker in the 
90 days after discharge from the index hospitalization (Table 1).  Propranolol (61%) was the 
most commonly dispensed index beta-blocker, followed by bisoprolol (19%), carvedilol (16%), 
and atenolol (3%). 
 
Following a slight increase in proportion of beta-blocker initiators between 2004 and 2005, the 
proportion remained relatively unchanged between 2005 and 2007 (Figure 1).  In general, those 
who initiated beta-blockers were younger and appeared healthier than those who did not.  For 
example, beta-blocker initiators were hospitalized less often and had fewer comorbid conditions 
in the year preceding index hospitalization as compared to patients who did not initiate beta-
blockers after discharge.  Furthermore, those who initiated beta-blockers were more likely to 
have also received specialized inpatient care and were more likely to have undergone invasive 
cardiac procedures (Table 1 and online supplement).   
 
Predictors of beta-blocker use 
Table 2 presents the results of the multivariable logistic regression model examining independent 
predictors of post-AMI beta-blocker initiation (see online supplement for full results).  Adjusted 
for other covariates in the model, the odds of initiating a post-AMI beta-blocker decreased 
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monotonically with increasing age (Table 2).  Undergoing coronary artery bypass graft (CABG) 
surgery (OR, 2.37; 95% CI, 2.00-2.81), percutaneous transluminal coronary angioplasty (PTCA; 
OR, 1.42; 95% CI, 1.31-1.54), and cardiac catheterization (OR, 1.14; 95% CI, 1.11-1.32) 
remained strong predictors of initiating post-AMI beta-blocker therapy (Table 2).  Use of certain 
types of drugs for cardiovascular conditions in the 6 months leading up to index hospitalization 
were also strong predictors of beta-blocker use after discharge, including use of ACE-inhibitors 
(OR, 1.19; 1.11-1.28), ARBs (OR, 1.15; 95% CI, 1.05-1.26) and beta-blockers (OR, 1.81; 95% 
CI, 1.67-1.96).   
 
Adherence to beta-blocker therapy 
Within the first 6 months after discharge, 513 (3.1%) subjects who received post-AMI beta-
blockers died and were excluded from both the 6-month PDC estimation.  A total of 961 (5.9%) 
of beta-blocker initiators died during the follow-up year and were excluded from the 12-month 
PDC estimation.  Monotonic decreases in mean 6- and 12-month PDC estimates were observed 
between 2004 and 2007.  Mean 6-month PDC was 64.5% in 2004, 62.2% in 2005, 60.3% in 
2006, and 58.4% in 2007.  Mean 12-month PDC was 59.3% in 2004, 57.3% in 2005, 55.2% in 
2006, and 53.8% in 2007.  The proportion of beta-blocker users who were adherent at 6 months 
following therapy initiation and at 12 months following initiation (Figure 2) also decreased over 
time (p for trend <0.001 for both 6- and 12-month PDC). 
  
DISCUSSION 
Among patients identified as being eligible for beta-blocker treatment following AMI 
hospitalization in RER, only two-thirds initiated such therapy between 2004 and 2007, despite 
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compelling evidence of substantial reductions in morbidity and mortality associated with such 
treatment.  This proportion is within the range of estimates previously observed in other 
countries.  For example, in Canada, 61% of patients initiated post-AMI beta-blocker therapy in 
British Columbia, between 2001 and 2004 [9] and 77% were initiators in Ontario over the same 
period [6].  The 67% that we observed was a substantial improvement over the 9% to 31% 
uptake observed by Avanzini and colleagues in Italy in 1983-1994 [13]. 
 
Adherence to and persistence with beta-blocker therapy in the 6 and 12 months following 
treatment initiation was low, and much lower than that observed in other studies [6,12,26].  We 
also observed that the mean PDC and the proportion of patients classified as adherent decreased 
over time, even though the proportion of patients surviving AMI hospitalization who initiated 
beta-blocker therapy was largely unchanged during this period.  These findings are in contrast 
with observations from the US and Canada which indicate that adherence with beta-blocker 
therapy was on the rise between the 1990s and 2003 [12,26].  A particular strength of our study 
is that it uses recent data.  Further investigation in other regions and countries using recent data is 
required to understand if our observed decrease in adherence is specific to RER, or to Italy, or if 
trends in other countries also regressed after 2003. 
 
Several demographic variables, frailty and comorbidity indicators, and factors related to index 
hospitalization were identified as independent predictors of post-AMI beta-blocker use.  
Consistent with a similar population-based study in Finland [27], we found that beta-blocker 
initiation was inversely associated with age.  In general, older individuals and those with 
conditions indicating illness and frailty were less likely to initiate beta-blockers after AMI.  It is 
 11 
possible that prescribing of drugs for secondary prevention may often be avoided in patients with 
poor prognoses, based on the belief that preventive strategies may confer little benefit while 
adding the burden of an additional treatment in these patients.  Providers may also be reluctant to 
prescribe beta-blockers to older patients because of concern of adverse events.   
 
An important limitation of our study is that we were unable to distinguish between patients who 
did not receive a beta-blocker prescription from a provider following AMI hospitalization and 
those that did receive a prescription but never filled it (so-called primary non-adherence) [28].  
Among post-AMI patients in other countries, it has been estimated that up to 1 in 5 patients 
exhibit primary non-adherence [28,29].  Thus, a substantial proportion of the 33% of patients 
that we identified as non-initiators may be patients who received a beta-blocker prescription but 
did not fill it.  Whether due to suboptimal prescribing or to primary non-adherence, it appears 
that many patients in RER who could benefit from beta-blocker therapy are not using it.  Indeed, 
results from several studies suggest that older patients benefit considerably from beta-blockade 
[18,30].  Other studies have also found that the patients who are least likely to receive post-AMI 
beta-blocker therapy may be those in whom beta-blockade confers the greatest benefit [8]. 
 
We found that patients who underwent invasive cardiac procedures during hospitalization for 
AMI (i.e. CABG, PTCA, and cardiac catheterization) were more likely to initiate beta-blocker 
therapy after discharge as compared to those patients who did not undergo such procedures.  
Consistent with prescribing decisions based on prognosis, this observation may reflect the notion 
that those who receive invasive procedure are those expected to have better prognoses and those 
that are expected to have better prognoses are those who are more likely to receive post-
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discharge beta-blocker therapy.  Alternatively, this finding may suggest that hospitals with the 
capacity and expertise to provide invasive cardiac treatment for AMI are also more likely to 
provide appropriate medical management, such as post-AMI beta-blocker treatment.  On a 
patient-level, this finding could reflect the notion that patients who consent to invasive 
procedures are more likely to initiate subsequent preventive health measures.  Regardless of the 
explanation, this finding is in stark contrast with results from other studies.  One US-based study 
found that patients receiving intensive in-hospital treatment, measured as the receipt of cardiac 
catheterization within 30 days of AMI, were less likely to receive post-AMI beta-blocker therapy 
[31].  In another study among US Medicare patients with AMI, geographic regions where 
invasive procedures are more common were less likely to provide beta-blocker therapy to their 
patients [32].  Additional research in RER should focus on the relation between post-AMI beta-
blocker use and geographic provision of intensive cardiac care in the region (i.e. hub and spoke 
[33]).   
 
Given the solid scientific foundation for post-AMI beta-blockade and the low concordance with 
such evidence-based care that we observed in routine practice, health policy actions may be 
warranted.  Quality improvement initiatives, such as pay-per-performance programs, could be 
established to encourage appropriate beta-blocker prescribing for eligible patients in accordance 
with guidelines.  In addition, educational programs targeting AMI survivors could improve 
patient adherence to appropriate beta-blocker therapy.  Such patient-directed activities could 
focus on those individuals who are least likely to receive appropriate care but in whom the 
benefits of such care confer the greatest benefit, such as older individuals. 
 
 13 
Our study has several additional limitations.  First, it is not possible to accurately identify those 
patients in whom beta-blockers are ineffective or not tolerated using administrative claims data 
and sufficient information to identify all patients with contraindications to therapy may be 
limited.  For example, we could not identify patients who may have received beta-blockers in the 
hospital, were intolerant, and subsequently discontinued therapy prior to discharge.  
Furthermore, we relied on definitions of contraindications used by previous investigators and we 
were unable to assess their validity in the RER database.  Thus, due to misclassification, we may 
have included in our cohort patients with relative contraindications that are not captured in 
administrative healthcare data.  Also, the regional policy of directly distributing medications to 
patients from hospital pharmacies both at discharge and for outpatient treatment could have 
resulted in a slight underestimate of post-AMI beta-blocker use since these data are not captured 
at an individual level in the RER database.  Finally, we used DDDs to estimate a proxy of days 
supply in order to derive the PDC.  However, DDDs are fixed units of measurement and may not 
always reflect prescribed daily doses for individual patients [25].  As a result, DDDs provide 
only a rough estimate of utilization.  It is possible that some PDC misclassification occurred, but 
this is not likely to have substantially affected the results. 
 
In conclusion, despite the well-documented benefits of beta-blockade after AMI, beta-blocker 
therapy remained underutilized in RER.  Utilization was less likely among older individuals and 
among those with indicators of frailty, such as multiple and various comorbid conditions, even 
though these patients may benefit from post-AMI beta-blockade.  Among those who did initiate 
post-AMI beta-blocker treatment, adherence to and persistence with such therapy was also low 
and decreased over time in RER between 2004 and 2007.     
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LEGENDS 
 
Figure 1. Proportion of patients surviving hospitalization for acute myocardial infarction 
with post-hospitalization beta-blocker initiation, 2004-2007  
 
Figure 2. Proportion of patients initiating beta-blocker therapy following hospitalization 
for acute myocardial infarction who were adherent, moderately adherent, and non-
adherent within the first 6 months of treatment (Panel A) and within the first year of 
treatment (Panel B), 2004-2007  
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TABLES 
 
Table 1.  Selected demographics and characteristics of acute myocardial infarction hospitalization survivors in 
Regione Emilia-Romagna, 2004-2007* 
 All patients 
hospitalized for 
AMI (n=24,367) 
Beta-blocker 
initiators (n=16,383) 
Beta-blocker non-
initiators 
(n=7,984) 
Age group, n (%)    
     <55 3,135 (12.9) 2,347 (14.3) 788 (9.9) 
     55-64 4,334 (17.8) 3,303 (20.2) 1,041 (13.0) 
     65-74 6,019 (24.7) 4,370 (26.7) 1,649 (20.7) 
     75-84 7,394 (30.3) 4,716 (28.8) 2,678 (33.5) 
     85+ 3,475 (14.3) 1,647 (10.1) 1,828 (22.9) 
Male, n (%) 15,584 (64.0) 10,845 (66.2) 4,739 (59.4) 
Primary or secondary diagnoses in prior year, n (%)    
     Congestive heart failure 793 (3.2) 384 (2.3) 409 (5.1) 
     Angina pectoris 372 (1.5) 262 (1.6) 110 (1.4) 
     Other ischemic conditions 665 (2.7) 458 (2.9) 207 (2.6) 
     Other cardiovascular diseases 2,447 (10.0) 1,426 (8.7) 1,021 (12.8) 
Pre-hospitalization medications, n (%)    
     Digoxin 982 (4.0) 536 (3.3) 446 (5.6) 
     ACE-inhibitors 7,837 (32.2) 5,348 (32.6) 2,489 (31.2) 
     Nitrates 4,732 (19.4) 3,062 (18.7) 1,670 (20.9) 
     Beta-blockers 5,710 (23.4) 4,385 (26.8) 1,325 (16.6) 
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     CCBs 5,917 (24.3) 4,036 (24.6) 1,881 (23.6) 
     ARBs 3,636 (14.9) 2,556 (15.6) 1,080 (13.5) 
Secondary diagnoses with high mortality risk at index 
admission, n (%) 
   
     Cancer 1,354 (5.6) 797 (4.9) 557 (7.0) 
     Renal disease 827 (3.4) 363 (2.2) 464 (5.8) 
     Pneumonia 3,611 (14.8) 1,974 (12.0) 1,637 (20.5) 
     Cerebrovascular disease 15,980 (65.6) 10,424 (63.6) 5,556 (69.6) 
     Any one of high-risk secondary diagnoses  16,439 (67.5) 10,703 (65.3) 5,736 (71.8) 
CCDG score in prior year, n (%)    
     0-1 11,346 (46.6) 7,687 (46.9) 3,659 (45.8) 
     2-3 9,804 (40.2) 6,628 (40.5) 3,176 (39.8) 
     4+ 3,217 (13.2) 2,068 (12.6) 1,149 (14.4) 
Index hospitalization length of stay, mean±SD 11.1±11.8 10.3±10.4 12.7±14.1 
CABG during index hospitalization, n (%) 1,082 (4.4) 838 (5.1) 244 (3.1) 
PTCA during index hospitalization, n (%) 13,784 (56.6) 10,250 (62.6) 3,534 (44.3) 
Cardiac catheterization during index hospitalization, n (%) 17,364 (71.3) 12,721 (77.6) 4,643 (58.2) 
SD=standard deviation; ACE=angiotensin-converting enzyme; CCBs=calcium channel blockers; ARBs=angiotensin II 
receptor blockers; CCDG=chronic condition drug groups; CABG=coronary artery bypass graft; PTCA=percutaneous 
transluminal coronary angioplasty 
* See online appendix for full list of baseline demographics and patient characteristics 
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Table 2. Selected independent predictors of beta-blocker initiation following acute myocardial 
infarction hospitalization discharge in Regione Emilia-Romagna, 2004-2007* 
Variable Odds Ratio 95% Confidence Interval 
Age group 
     <55  
     55-64 
     65-74 
     75-84 
     85+ 
 
Referent 
0.97 
0.82 
0.66 
0.46 
 
- 
0.87-1.09 
0.73-0.91 
0.59-0.73 
0.41-0.53 
Sex 
     Female  
     Male 
 
Referent 
0.95 
 
- 
0.89-1.01 
Primary or secondary diagnoses in prior year 
     Congestive heart failure 
     Angina pectoris 
     Other ischemic conditions 
     Other cardiovascular diseases  
Pre-hospitalization medications  
     Digoxin 
     ACE-inhibitors 
     Nitrates 
     Beta-blockers 
     CCBs 
 
0.87 
1.27 
1.26 
0.95 
 
0.97 
1.19 
1.00 
1.81 
1.09 
 
0.71-1.08 
0.99-1.62 
0.99-1.61 
0.84-1.07 
 
0.84-1.12 
1.11-1.28 
0.92-1.09 
1.67-1.96 
1.01-1.17 
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     ARBs 1.15 1.05-1.26 
Secondary diagnoses with high mortality risk at index 
admission 
     Cancer 
     Renal Disease 
     Pneumonia 
     Cerebrovascular disease 
     Any one of high-risk secondary diagnoses 
CCDG score in prior year 
     0-1  
     2-3 
     4+ 
 
 
0.94 
0.66 
0.88 
0.93 
1.06 
 
Referent 
1.02 
1.02 
 
 
0.83-1.06 
0.56-0.76 
0.81-0.96 
0.76-1.15 
0.85-1.31 
 
- 
0.94-1.11 
0.91-1.15 
Index hospitalization length of stay (for every 5-day 
increase) 
CABG during index hospitalization 
PTCA during index hospitalization 
Cardiac catheterization during index hospitalization 
0.96 
 
2.37 
1.42 
1.21 
0.95-0.97 
 
2.00-2.81 
1.31-1.54 
1.11-1.32 
SD=standard deviation; ACE=angiotensin-converting enzyme; CCBs=calcium channel blockers; 
ARBs=angiotensin II receptor blockers; CCDG=chronic condition drug groups; CABG=coronary artery 
bypass graft; PTCA=percutaneous transluminal coronary angioplasty 
* See online appendix for full list of predictors of beta-blocker initiation 
 
 
